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Zoledronic acid has shown indirect anticancer effects on angiogenesis, the tumor microenvironment and immune
responses. Its immunological action is exerted, at least in part, via its modulating properties. The aim of this study was
to investigate the in vitro effects of zoledronic acid on the dendritic cells of melanoma patients. Peripheral blood
samples were collected from 26 patients with melanoma and 11 healthy donors. Dendritic cells were derived from
purified monocytes, and zoledronic acid (ZA) was added on the first day of culture. The phenotype and function of the
generated cells were evaluated by flow cytometry. The ZA-treated monocytes from patients with early-stage disease
generated DCs characterized by reduced endocytic activity and increased allostimulatory capacity compared with the
untreated samples, allowing restoration of the DC function observed in normal subjects. In contrast, the ZA-treated
monocytes from patients at stage III generated cells with higher CD14 antigen expression and endocytosis than the
untreated samples. Therefore, in melanoma patients, the in vitro ZA effects differ according to the progression of the
disease. In addition, our preliminary results appear to suggest that ZA effects are also influenced by the expression of
CD14 antigen, indicating that the DC phenotype together with clinical characteristics must be considered in the choice
of patients to be treated with ZA. Our work focus on the effect of ZA on monocyte-derived DCs from melanoma
patients, showing that the effects of therapeutic doses of this drug might be mediated at least in part by modulation of
myeloid cell function.
Introduction
Cutaneous melanoma is an aggressive tumor with a high meta-
static potential and marked resistance to the currently available
antitumor therapy strategies.1 The high mortality rate of malignant
melanoma, the poor efficacy of chemotherapy in advanced stages
of the disease, and the high toxicity of the classical regimens have
stimulated intensive research for new alternatives to the therapy.1
It has been previously demonstrated that the nitrogen-con-
taining bisphosphonate pamidronate is able to induce apoptosis
and to inhibit proliferation in melanoma cells in vitro.1,2
Aminobisphosphonates (ABPs) are synthetic compounds that
have shown direct and indirect anticancer actions.3 A pro-
nounced effect on the immune system, which might contribute
to their in vivo anti-tumor activity, has been described.4
The enhancement of immune-mediated antitumor activity
appears to be exerted, at least in part, through the expansion of
gd T-cells.3
Zoledronic acid (ZA), one of the newer generation nitrogen-
containing BPs, has been particularly well investigated, both pre-
clinically and in clinical practice.4 ZA inhibits the enzyme farne-
syl diphosphate synthase (FPPS), which plays a role in the
mevalonate pathway and in the subsequent prenylation of small
GTPases proteins such as Ras. These molecules are involved in
the intracellular signaling cascades and are essential for osteoclast
activity and survival.4,5
Recently, it has been demonstrated that gd T-cells activated by
ZA play an adjuvant role, linking innate and acquired immunity,
through interactions with dendritic cells (DCs) in a way that ampli-
fies the proliferation of tumor antigen-specific CD8C T cells.6-8
DCs are unique specialized antigen-presenting cells that are
capable of stimulating naive T cells during primary immune
responses and of inducing antigen-specific cytotoxic T lympho-
cytes (CTLs) and helper T cells.9
The interaction between tumor and dendritic cells is an emerg-
ing theme. Most tumors are infiltrated by DCs, which may
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determine the balance of several (often opposing) molecular inter-
actions that regulate the recognition, uptake, processing and ulti-
mately presentation of cellular antigens to the immune system.
DCs also interact with living tumor cells and have non-immuno-
logic effects on tumor cells and their microenvironment.10
Many ongoing clinical trials make use of monocyte-derived
DCs as vaccines in cancer patients; therefore the aim of this study
was to analyze the effects of ZA on the properties of DCs derived
from the peripheral blood monocytes of melanoma patients to
investigate its potential use in reversing the immunosuppressive
environment of the tumor.
Results
ZA effects on cultured cell morphology
Using cells from 10 melanoma patients, we investigated the
morphological profile of cells harvested on day 7 of culture after
stimulation with LPS. The cells derived from cultures displayed
features of mature myeloid DCs, including irregular membrane
ruffling, dendrites and a laterally positioned nucleus.
ZA treatment did not induce substantial changes in the mor-
phological appearance of the cells (Fig. 1).
ZA effects on dendritic cell phenotype and function
It is known that the generation of DCs from the monocyte
population is characterized by the loss of CD14 antigen. There-
fore, we used this marker to assess DC generation on the sixth
day of culture using cells from 26 melanoma patients.
Collected data were examined using two different analytical
approaches.
First analytical approach
We evaluated the entire patient population and patients
divided on the basis of clinical stage (stage I-II, stage III, and
stage IV) in comparison with the healthy control group. The
effects of ZA treatment were thus investigated (Fig. 2).
As previously reported,11 melanoma patients exhibit a higher
percentage of CD14-expressing cells than healthy controls
(15.5§ 4.4% vs. 5.1§ 1.4%, respectively; P > 0.05). CD14
expression was highly variable among the patients (range: 0.6%–
94.7%), with high values especially observed for patients in a
more advanced stage of the disease (CD14C cells: 32.6§ 10.3%;
P D 0.009, compared with HCs).
The expression levels of HLA-DR antigen in immature DCs
and those of CD40, CD80, CD83, and HLA-DR in the mature
DCs from the patients were found to be similar to those of the
controls.
However, the immature DCs obtained from melanoma
patients at all stages of the disease showed a significantly higher
endocytic activity than those from the healthy donors. The ability
of the mature DCs obtained from patients to induce allogeneic T
cell proliferation was reduced, particularly in the group of
patients in disease stage IV, without significant differences from
the control DCs.
ZA treatment did not substantially modify the percentage of
CD14-expressing cells compared with the untreated samples. In
fact, the ZA treated cells did not show a significant decrease in
CD14 expression, except for those from the stage III patients,
which exhibited a significant increase in expression compared
with the baseline sample (10.14 § 5.1% vs. 7.7 § 4.7%;
P < 0.05). In addition, the ZA treated immature cells did not
show a significant increase in HLA-DR antigen expression com-
pared with the untreated cells (data not shown).
Endocytic activity was modulated to different extents by ZA
treatment. In fact, it induced a significant reduction in endocytic
activity in the cells from patients with early disease (DMFI: 60.1§
17.6 vs. 88.4§ 15.0; P < 0.05), whereas a significant increase was
found in the cells from patients at stage III (DMFI: 243.4§ 59.2 vs.
119.8§ 33.1; P< 0.05) compared with the untreated samples.
ZA treatment did not significantly affect the phenotype of
mature DCs, with similar values of HLA-DR, CD40, CD80,
and CD83 expression observed between the treated and
untreated groups.
However, ZA treatment did induce a
significant increase in allostimulatory
capacity in the cells from both the com-
bined patient population and early-stage
patients compared with the untreated
samples (15.2§ 1.7 vs. 13.2§ 1.4 and
5.5 § 2.2 vs. 13.8 § 2.0, respectively;
P < 0.05).
Second analytical approach
As we observed a variable trend in
CD14 antigen expression in the cells
from melanoma patients, we performed
an additional analysis by dividing the
population into two groups on the basis
of CD14 expression: one with levels
comparable to normal controls (group A:
4.05§ 0.95%) and the other one with 1
Figure 1. Zoledronic acid treatment does not modify the morphology of monocyte-derived DCs.
Mature DCs were differentiated from untreated (A) and ZA-treated (B) CD14C cells from melanoma
patients. DC preparation was examined by light microscopy after May–Grunwald-Giemsa staining. A
representative experiment using the cells from a patient in stage III of the disease is shown. DCs, den-
dritic cells; ZA, zoledronic acid.
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SD more than the mean of the controls
(group B: 40.13§ 8.4%).
Groups A and B were composed of
17 patients (7 at stages I-II, 6 at stage
III, and 4 at stage IV) and 9 patients
(3 at stages I-II, 1 at stage III, and 5 at
stage IV), respectively. The effects of
zoledronic acid in the cells from these
groups are displayed in Figure 3.
In group A, ZA treatment induced a
significant increase in the percentage of
CD14-expressing cells in comparison
with the untreated samples (6.4§ 1.3%
vs. 4.05 § 0.95%; P D 0.0024); this
increase was observed in cells from
patients in all disease stages, reaching a
significant value only in the patients
with early disease (4.1 § 1.3% vs.
2.3§ 0.7%; P D 0.04). Although ZA
treatment increased the percentage of
CD14-expressing cells, the obtained val-
ues were still comparable to those ones
of the healthy subjects. Conversely, in
group B, ZA treatment induced a sub-
stantial reduction in CD14-expressing
cells (24.0 § 8.1% vs. 40.1 § 8.4%;
P D 0.0056), with significant values in
stages I-II and IV (6.3 § 2.8% vs.
15.3 § 2.0% and 28.1 § 14.6% vs.
51.8§ 13.2; P D 0.03 and P D 0.023,
respectively).
The cells from the patients in both
groups A and B showed an endocytic
activity that was significantly higher
than that for the cells from the healthy controls (130.1 §
19.4 and 106.1 § 15.8 vs. 49.0 § 6.2; P D 0.003 and
P D 0.002, respectively). In group A, the ZA-treated cells
showed an increase in this activity compared with the
untreated samples (183.3§ 40.4 vs. 130.1§ 19.4), particu-
larly notable for stage III of the disease (250.8 § 67.8 vs.
133.8 § 34.6; P D 0.046); in group B cells, ZA treatment
induced low effects.
Figure 2. Effects of zoledronic acid treat-
ment on the phenotype (A) and function
(B) of monocyte-derived DCs. CD14 expres-
sion and phagocytic activity (evaluated by
FITC-dextran uptake) were measured using
immature DCs. HLA-DR, CD40, CD80, and
CD83 expression and allostimulatory activ-
ity (assessed by DNA staining for S phase
of the cell cycle) were measured using
mature DCs. Bars represent the mean §
SEM of percent positive cells or the mean
fluorescence intensity (MFI) of each obser-
vation. Black bars indicate the ZA-treated
samples. Significant differences are indi-
cated: *P < 0.05, **P < 0.01. HC, healthy
controls; DMFI, difference in MFI between
the cell fractions of the same sample incu-
bated at 37C and 0C, respectively
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The expression of costimulatory molecules (CD40 and
CD80), CD83, and HLA-DR did not differ between groups A
and B and the controls. However, in group A (both combined
population and early-stage patients), the ZA-treated samples
compared with untreated samples showed a significant reduc-
tion in both CD40 (2206 § 151.8 vs. 2389 § 148.8 and
2057§ 322.7 vs. 2414§ 317.6; P D 0.02 and P D 0.001,
respectively) and CD80 (145.9§ 11.6 vs. 163.7§ 10.1 and
135.4§ 11.4 vs. 160.1§ 13.0; P D 0.04 and P D 0.02, respec-
tively). Following ZA treatment, the cells from patients at
stages I-II of this group showed a significant increase in HLA-
DR antigen (364.8§ 50.0 vs. 320.6§ 40.2; P D 0.03). In
addition, ZA treatment induced a low reduction in the percent-
age of CD83-expressing cells and a weak increase in allostimu-
latory activity.
In contrast, in group B cells, ZA treatment did not induce any
significant effect.
Discussion
In melanoma, due to its high immunogenicity, the role of
DCs is crucial for understanding its pathogenesis and developing
efficacious immunotherapy.11 In the present work, we found that
monocyte-derived immature DCs from melanoma patients in
advances stages show phenotypical/functional changes, as previ-
ously observed.11
Zoledronic acid is used for the prevention of osteoporosis and
the treatment of bone metastasis in multiple myeloma and other
cancers.12-14
In vitro and in vivo studies indicate that, in addition to
their well-known antiosteoclastic activity, bisphosphonates
exert other direct and indirect antitumor effects, which could
contribute to their efficacy in metastatic cancer treatments.
Among the several bisphosphonates, zoledronic acid is consid-
ered to be more potent than the others with regard to antitu-
mor activity.4,6 One of the mechanisms implicated in the
antitumor effect of ZA is the inhibition of the enzyme farnesyl
diphosphate synthase, which results in the altered synthesis of
enzymes such as Rho, Rac, and Rab, which are thought to be
involved in cell proliferation, cell motility, angiogenesis, and
cell migration.15-22 Several in vitro and in vivo models provide
evidence that ZA also exerts antitumor effects by inducing
immunological activities.
Recently, it has reported that ZA blocks the interaction
between mesenchymal stem cells and breast cancer cells, which is
thought to reduce the effect of mesenchymal stem cells on the
progression of breast cancer.22,23
However, the most investigated and recognized effect of ZA is
the induction of inflammatory responses, which are accompanied
by the expansion of gd T cells.24
These gd T cells activated by ZA play an adjuvant role, link-
ing innate and acquired immunity, through interactions with
DCs in a way that amplifies the proliferation of tumor antigen-
specific CD8C T cells.6-8 In fact, it has been reported25-27 that a
rapid and robust proliferative expansion of gd T cells with
antitumor activity can be induced by ZA treatment of monocytes
or dendritic cells. Therefore, gd T cell activation by ZA is highly
dependent on the presence of APCs, including DCs.7,28-30
There are few studies about the effects of ZA on DC genera-
tion and maturation that differ in terms of experimental design
and in the observed phenotypic and functional DC aspects.6
However, these studies agree that this compound exerts its
immunological action, at least in part, by modulating DC
properties.
Fiore et al.25 have shown that ZA improves the immunosti-
mulatory ability of immature and mature DCs toward unconven-
tional gd and conventional ab T cells.
Bringmann et al.24 reported that the application of high-dose
ZA has inhibitory effects on DC differentiation and activation,
suggesting that the immunosuppressive effects may have a nega-
tive impact on tumor surveillance or control of minimal residual
disease or promote infectious complications.
Other studies,31,32 demonstrated that ZA modulates the dif-
ferentiation, maturation, and functions of DCs, indicating that
ZA may act at the differentiation stage of DCs to suppress the
generation and maturation phenotype of DCs.
Recently, we demonstrated in normal subjects that ZA treat-
ment did not affect DC differentiation from monocytes but
modulated their maturation process, as shown by its inhibitory
effects on both phenotypic and functional features.6
Here, we show that in melanoma patients, the in vitro ZA
effects differ according to the progression of the disease. Indeed,
ZA-treated monocytes from patients with early-stage disease gen-
erated DCs characterized by reduced endocytic activity and
increased allostimulatory capacity compared with untreated sam-
ples, allowing restoration of the DC function observed in normal
subjects. In contrast, ZA-treated monocytes from patients at stage
III generated cells with a higher CD14 antigen expression and
higher endocytosis than untreated samples.
Therefore, these results are similar to those observed in a
recent work,33 showing that the progressively reduced cytotoxic-
ity against the melanoma cells of purified gd T cells from mela-
noma patients, after IL-2/zoledronate expansion, depended on
the stage of the disease.
However, the results obtained by a further analysis evaluating
the expression of CD14 antigen appear to suggest that the DC
phenotype together with clinical characteristics must be consid-
ered in the choice of patients to be treated with ZA. Furthermore,
this observation derived from a low number of patients deserves
further investigation in a larger sample.
Tumor cells use several mechanisms to escape the immune
system. DCs, which are important cells for the initiation of a spe-
cific antitumor T-cell response, are also possible target cells sus-
ceptible to tumor-mediated immunosuppression.
Takahara et al.7 suggest that the physical size of the immune
response is crucial for successful antitumor therapy and that new
methods to increase the immune response are needed for further
therapeutic progress.
Studies to revert or overcome gd lymphocyte paralysis have to
be encouraged to evaluate possible therapeutic strategies aimed at
controlling melanoma.33
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Interestingly, it has been shown that cop-
ulsing immature DCs with zoledronate
and melanoma-derived peptides
increased antigen-specific CD8C T cells
in healthy individuals, confirming that
the adjuvant effect of ZA can enhance
responses to cross-presented tumor
antigens.7
In conclusion, our work focused on
the effect of ZA on monocyte-derived
DCs from melanoma patients, showing
that the effects of therapeutic doses of this
drug might be mediated at least in part by
modulation of myeloid cell function.
Material and Methods
Study population
The study protocol was approved by
the local Ethics Committee review board
(protocol 2806/09), and informed donor
consent was obtained in accordance with
the Declaration of Helsinki. In this
study, we included 26 patients (n D 10
females and n D 16 males) with a new,
histologically confirmed diagnosis of
cutaneous melanoma. This population
was divided into three groups based on
the clinical stage: no evidence of regional
lymph node or distant metastasis (stages
I-II; n D 10), lymph node involvement
without distant metastasis (stage III; n D 7), the presence of dis-
tance metastasis (stage IV; n D 9). None of these patients pre-
sented with a history of neoplastic diseases (except cutaneous
melanoma), infectious diseases or others disorders, therapies or
conditions known to interfere with DC expression. Blood sam-
ples were drawn from the melanoma patients prior to
Figure 3. Effects of zoledronic acid treat-
ment on the phenotype (A) and function (B)
of monocyte-derived DCs. The patient pop-
ulation was divided into two groups based
on CD14 expression: one with levels compa-
rable to normal controls (group A) and the
other one with 1 SD more than the mean of
the controls (group B). Bars represent the
mean§ SEM of percent positive cells or the
mean fluorescence intensity (MFI) of each
observation. Black bars indicate the ZA-
treated samples. Statistical significance is in
comparison to untreated samples, unless
otherwise indicated: *P < 0.05; **P < 0.01;
xP< 0.05, xxP< 0.01, xxxP< 0.001, untreated
samples vs. healthy controls; yP < 0.05, yyP
< 0.01, ZA-treated samples vs. healthy con-
trols. HC, healthy controls; Pts, overall
patient population; DMFI, difference in MFI
between the cell fractions of the same sam-
ple incubated at 37C and 0C, respectively.
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chemotherapeutic and/or radiation treatment. None of these
patients was previously treated for melanoma.
Drug
Zoledronic acid (ZA), kindly provided by Novartis Pharma
AG, was added on the first day of culture to evaluate its
immuno-modulatory effects on DCs. The drug concentration
was selected on the basis of a previous study,6 in which we dem-
onstrated the high toxic effect of ZA on culture-derived cells at
concentrations of 5 and 10 mmol/L; therefore, we used the con-
centration of 1 mmol/L, the maximum plasma level reached after
the standard clinical administration of 4 mg of the drug in
15 min for the treatment of bone metastasis.6 The same effect
was observed in further experiments performed on a small group
of melanoma patients (data not shown).
Generation of dendritic cells
Peripheral blood was collected from 26 patients with mela-
noma and from 11 healthy donors with a similar gender and age
distribution.
Following venous blood collection in heparinised tubes,
peripheral blood mononuclear cells (PBMCs) were obtained by
density gradient centrifugation using Histopaque 1077 (Sigma,
St Louis, MO, USA). CD14C monocytes were isolated from
PBMCs by magnetic bead separation using anti-CD14 microbe-
ads (Miltenyi Biotech) to a purity that was generally >90%, as
determined by FACS analysis.34
Briefly, PBMCs were incubated with microbeads conjugated
with monoclonal mouse anti-human CD14 antibodies for
15 min on ice and washed in phosphate-buffered saline (PBS)
containing 0.5% bovine serum albumin and 2 mM ethylenedi-
amine tetraacetic acid (EDTA). The labeled and positively
enriched cells were eluted from magnetic columns by the removal
of the columns from the magnetic device. The purified CD14C
cells were resuspended at a concentration of 1 £ 106 cells/mL
and cultured for 6 d in multi-well tissue culture plates in RPMI-
1640 (Gibco Laboratories) supplemented with 10% fetal calf
serum (FCS; Euroclone SpA), 2 mM L-glutamine (Euroclone
SpA), 100 mg/mL streptomycin and 100 IU/mL penicillin
(Sigma) in the presence of 50 ng/mL recombinant human granu-
locyte-macrophage colony-stimulating factor (GM-CSF; Pepro-
Tech EC Ltd) and 50 ng/mL recombinant human interleukin 4
(IL-4; PeproTech Inc.).
For maturation, DCs were cultured with 100 ng/mL of bacte-
rial lipopolysaccharide (LPS; Sigma-Aldrich) for 24 h.
DCs were harvested after 6 or 7 d of culture and used to ana-
lyze cell morphology and cell-surface markers.
Morphological evaluation
To evaluate the morphology of the cultured cells, cytospin
slides were prepared by cytocentrifuging 5 £ 104 cells/mL at
800 £ g for 10 min (Shandon Cytospin-2 Centrifuge, GMI
Inc.). The slides were air-dried and fixed with methanol (Carlo
Erba Reagenti SpA), stained with May–Grunwald-Giemsa (Carlo
Erba Reagenti SpA) and examined by light microscopy (Olym-
pus Corporation).
Flow cytometric analysis
The antibodies used for cell surface staining included anti-
CD14 and anti-human leukocyte antigen D-related (HLA-DR)
(Immunotools) and anti-CD40, anti-CD80, and anti-CD83
(Immunotech SAS) conjugated to fluorescein isothiocyanate
(FITC) or phycoerythrin (PE). Data acquisition and analysis were
performed with Epics-XL (Beckman Coulter Inc.) with Expo32
Software. Five thousand events were acquired for each sample.
DCs were gated according to their light-scattering properties,
and dead cells were excluded from the analysis.
The results were expressed as a percentage of positive cells or
as the mean fluorescence intensity (MFI) of positive cells.
Uptake of FITC–dextran
Mannose receptor-mediated endocytosis was measured as the
cellular uptake of FITC-dextran (Sigma-Aldrich Co) using cyto-
fluorimetric analysis. Approximately 1 £ 106 immature ZA-
treated or untreated cells were incubated in media containing
FITC-dextran (2 mg/mL; Sigma) for 60 min at 37C or on ice
(the latter for the assessment of background staining due to non-
specific external binding).
After incubation, the cells were washed twice with PBS to
remove the excess dextran and fixed in cold 1% formaldehyde
(Bio Optica Milano SpA). The cells were then analyzed using
flow cytometry. At least 5000 gated events were evaluated for
each condition. DCs were gated based on their light-scattering
properties, and dead cells were excluded from the analysis. The
level of antigen uptake by DCs was expressed as the difference in
MFI (DMFI) between the cell fractions of the same sample incu-
bated at 37C and 0C, respectively.
Allogeneic T cell proliferation assay
The primary T cell stimulatory capacity of DCs was tested in
an allo-mixed lymphocyte reaction (MLR).
Allogeneic purified T cells, derived from the same donor, were
used as the responder cells in 96-well round-bottomed tissue cul-
ture plates in a culture volume of 200 mL. All experiments were
performed in triplicate. Graded numbers of stimulator cells were
added to 2 £ 105 responder cells; control cultures, used to evalu-
ate the background proliferation, only contained responder or
stimulator cells.
After 6 d of culture in 5% CO2 at 37
C, the cells were har-
vested, counted and diluted to approximately 1 £ 106 cells/mL
and fixed in 70% ethanol. Proliferation was assessed using flow
cytometry for the S phase of the cell cycle with propidium iodide
(PI) staining for DNA (20 mg/mL; eBioscence Inc.). Data acqui-
sition and analysis were performed using an Epics-XL (Beckman
Coulter) with MultiCycle software.
Statistical analyses
A statistical analysis was performed either on the entire popu-
lation or by dividing the patients based on clinical stage using
GraphPad Prism software (GraphPad Software Inc.).
The data were expressed as the mean§ standard error of the
mean (SEM). The statistical significance of the differences
between the ZA-treated and untreated samples was determined
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by a paired two-tailed Student’s t test; an association was consid-
ered statistically significant when P < 0.05.
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